Abstracts tagged "anti-TNF therapy and tolerance"

Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Hélène Vallet¹, Sophie Rivière², Alban Deroux³, Guillaume Moulis⁴, Olga Addimanda⁵, Carlo Salvarani⁶, Marc Lambert⁷, Philip Bielfeld⁸, Pascal Sève⁹, Jean Sibilia¹⁰, Jean Baptiste Fraison¹¹, Yoland Schoindre¹², Isabelle Marie¹³, Laurent Perard¹⁴, Thomas Papo¹⁵, Damien Sène¹⁶, Gaelle Leroux¹⁷, Valerie Royant¹⁸, Antoinette Perlat¹⁹, Xavier Mariette²⁰, Olivier Lidove²¹, Olivier Fain²², Claire De Moreuil²³, Gilles Blaison²⁴, Phuc LE Hoang²⁵, Eric Hachulla²⁶, Bertrand Wechsler²⁷, Barham Bodaghi²⁸, Patrice Cacoub²⁹ and David Saadoun³⁰, ¹Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal Medicine, Lapeyronie, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Internal Medicine department, Toulouse, Toulouse, France, ⁵S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷CHRU Lille, Lille, France, ⁸CHU de Dijon, Dijon, France, ⁹Internal medicine, CHU Lyon, Lyon, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Hôpital Jean Verdier, Bondy, France, ¹²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ¹³CHU de Rouen, Rouen, France, ¹⁴Hospices civils de Lyon, Lyon, France, ¹⁵Hôpital Bichat, Paris, France, ¹⁶Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁸Chartres, Chartres, France, ¹⁹Internal medicine, CHU de Rennes, Rennes, France, ²⁰rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ²¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ²²Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ²³CHU, Brest, France, ²⁴Internal medicine, CHR, Colmar, France, ²⁵Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, ²⁶Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ²⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²⁸Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, ²⁹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].